Rocket Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Rocket Pharmaceuticals's estimated annual revenue is currently $4M per year.
- Rocket Pharmaceuticals received $50.0M in venture funding in November 2018.
- Rocket Pharmaceuticals's estimated revenue per employee is $16,653
- Rocket Pharmaceuticals's total funding is $552.8M.
Employee Data
- Rocket Pharmaceuticals has 242 Employees.
- Rocket Pharmaceuticals grew their employee count by 7% last year.
Rocket Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Rocket Pharmaceuticals?
Rocket Pharmaceuticals, Ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. For more information, please visit www.rocketpharma.com.
keywords:N/A
$552.8M
Total Funding
242
Number of Employees
$4M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Rocket Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Investor Relations | Reveal Email/Phone |
2 | Associate Director, Employee Communications | Reveal Email/Phone |
3 | Senior Director SEC Reporting and Technical Accounting | Reveal Email/Phone |
4 | EH&S Senior Specialist | Reveal Email/Phone |
5 | Director AAV R&D | Reveal Email/Phone |
6 | Director (Function Head), Corporate Communications | Reveal Email/Phone |
7 | Associate VP | Reveal Email/Phone |
8 | Senior Manager | Reveal Email/Phone |
9 | Executive Assistant | C-Suite | Reveal Email/Phone |
10 | Associate Director, Procurement and Business Operations | Reveal Email/Phone |
Rocket Pharmaceuticals News
Zero analysts have issued estimates for Rocket Pharmaceuticals' earnings, with the highest EPS estimate coming in at ($0.63) and the lowest...
Rocket Pharmaceuticals (NASDAQ:RCKT Get Rating)'s stock had its buy rating reaffirmed by Needham & Company LLC in a report issued on...
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences. March 29, 2022 07:00 AM Eastern Daylight Time. CRANBURY, N.J.--(BUSINESS WIRE)--Rocket...
CRANBURY, N.J.--(BUSINESS WIRE)--Mar 22, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces updated preliminary clinical data from its Phase 1 trial of R ...
CRANBURY, N.J.--(BUSINESS WIRE)--Mar 9, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the U.S. Food and Drug Administration (FDA) has granted R ...
Other Companies in new york
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $38.6M | 242 | N/A | N/A |
#2 | $60.4M | 242 | 0% | N/A |
#3 | $3.5M | 242 | 6% | N/A |
#4 | $81.2M | 242 | 2% | N/A |
#5 | $15M | 242 | -1% | N/A |
Rocket Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-11-27 | $50.0M | Undisclosed | BofA Merrill Lynch | Article |